AMPEL BioSolutions

AMPEL BioSolutions is a United States precision medicine company headquartered in Charlottesville, Virginia. It was founded to bring personalized precision medicine to patients, especially those living with autoimmune and inflammatory diseases, whose immune systems the company describes as complex, dynamic and not accurately assessed by current technologies. The company's founders, Amrie Grammer and Peter Lipsky, are described on its website as internationally recognized scientists and successful entrepreneurs who combined world-class science with business acumen. AMPEL's core technology is the AMPEL Genomic Platform (AGP®), which supports genomic blood and biopsy tests for patients. According to the company, the platform is used to evaluate disease status, identify cells, functions and pathways, and predict flares and drug targets. AMPEL states that its technology covers more than 95% of all known genes and is disease agnostic, giving it capacity to expand into additional disease areas. The company frames its offering as "One Platform, Many Solutions" and as "Lifetime Disease Management," built around the concept of a patient's "Genomic Fingerprint®." AMPEL's clinical product line includes LuGENE®, a lupus test that the company says is available through sites across the United States and is designed to predict flares before they happen and to provide specific information about a patient's disease abnormalities, supporting evidence-based treatment decisions. The company has announced DermaGENE® for the second half of 2026 and WellGENE™ for the second half of 2027. AMPEL also pursues co-development, licensing and complementary biomarker opportunities across lupus, dermatology (psoriasis, eczema/atopic dermatitis, scleroderma, lupus), cardiology, arthritis (OA, RA, LA), nephrology, fibromyalgia, infection and oncology. AMPEL positions itself at the intersection of RNA analytics, machine learning and clinical decision support. Its LuGENE® lupus test was announced as a launch to predict flares and drug targets, with results revealed in the peer-reviewed journal Genome Medicine and made available to patients through a US follow-on study. The company has also entered the molecular diagnostics (MDx) market with lupus and dermatology gene expression assays. Recognition has followed. In 2023 AMPEL was recognized as Virginia's Innovator-of-the-Year by CBIC, and the Coalition of 21st Century Precision Medicine elected AMPEL to membership. The company has also been selected as a member of the ARPA-H Customer Experience Hub Spoke Network, and its founder Amrie Grammer has presented the company's vision at the 2024 Precision Health Summit. AMPEL's news page highlights coverage on Bloomberg Markets, a Virginia Workforce Award, and research noting that lupus and coronary artery disease share genetic risk factors.

AMPEL BioSolutions was founded to bring personalized precision medicine to patients, especially those with autoimmune and inflammatory diseases. The company's founders, Amrie Grammer and Peter Lipsky, are described as internationally recognized scientists and successful entrepreneurs whose success has combined world-class science with business acumen. The company is headquartered in Charlottesville, Virginia, United States. The company built its business around the AMPEL Genomic Platform (AGP®), which supports genomic blood and biopsy tests. AMPEL states that its technology covers more than 95% of all known genes and is disease agnostic, giving it capacity to expand into additional disease areas. The platform is used to evaluate disease status, identify cells, functions and pathways, and predict flares and drug targets. After nine years in business, AMPEL entered the molecular diagnostics (MDx) market with lupus and dermatology gene expression assays. Its first product, the LuGENE® LDT blood test, was launched at several lupus practices around the country, including those in medical centers, concierge practices and healthcare systems, as a practical decision support biomarker test for patients with lupus. AMPEL announced that LuGENE® predicts flares before they happen and provides specific information about a patient's disease abnormalities leading to symptoms, allowing physicians to make evidence-based decisions regarding therapy, including whether a patient is stable on their current therapeutic regimen. The results were revealed in the peer-reviewed journal Genome Medicine and made available to patients through a US follow-on study. AMPEL has announced a product roadmap that includes DermaGENE® in the second half of 2026 and WellGENE™ in the second half of 2027. The company also pursues co-development, licensing and complementary biomarker opportunities across lupus, dermatology (psoriasis, eczema/AD, scleroderma, lupus), cardiology, arthritis (OA, RA, LA), nephrology, fibromyalgia, infection and oncology. In 2023, AMPEL was recognized as Virginia's Innovator-of-the-Year by CBIC. The Coalition of 21st Century Precision Medicine elected AMPEL to membership, and the company was ranked by Nature among the top precision medicine companies. AMPEL was also selected as a member of the ARPA-H Customer Experience Hub Spoke Network, whose other corporate Hub Spoke members include Verily, Datavant, Velsara, QuidelOrtho and Biolabs. At the 2024 Precision Health Summit, Amrie Grammer presented a vision of how precision medicine can reshape autoimmune and inflammatory disease treatment.

• 2024

  Amrie Grammer presented AMPEL's vision at the 2024 Precision Health Summit.

• 2023

  AMPEL was recognized as Virginia's Innovator-of-the-Year by CBIC.

• LuGENE® lupus test launched to predict flares and drug targets.

• AMPEL entered the MDx market with lupus and dermatology gene expression assays after nine years in business.

• AMPEL was selected as a member of the ARPA-H Customer Experience Hub Spoke Network.

• The Coalition of 21st Century Precision Medicine elected AMPEL to membership.

Personalized precision medicine using RNA analytics and predictive AI for autoimmune and inflammatory diseases; "One Platform, Many Solutions" and "Lifetime Disease Management."

• LuGENE®

  Lupus LDT blood test that predicts flares before they happen and provides information about a patient's disease abnormalities to support evidence-based treatment decisions.

• DermaGENE®

  Dermatology gene expression assay announced for launch in H2 2026.

• WellGENE™

  Wellness product announced for launch in H2 2027.

• AMPEL Genomic Platform (AGP®)

  Genomic platform supporting blood and biopsy tests to evaluate disease status, identify cells, functions and pathways, and predict flares and drug targets.

1. 1Home - AMPEL BioSolutionsampelbiosolutions.com
2. 2About AMPEL - AMPEL BioSolutionsampelbiosolutions.com
3. 3Company - AMPEL BioSolutionsampelbiosolutions.com
4. 4Products - AMPEL BioSolutionsampelbiosolutions.com
5. 5Ampel BioSolutions (United States) - Wikidatawikidata.org